HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (17) Citing Articles via Google Scholar Google Scholar Articles by Kostadima, E. Articles by Papamichalopoulos, A. Search for Related Content PubMed PubMed Citation Articles by Kostadima, E. Articles by Papamichalopoulos, A.

Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma

¹ 10th Respiratory Dept, Athens Chest Hospital, and ² University of Athens School of Medicine, University of Athens, Athens, and ³ Paediatric Pulmonology Unit, Dept of Paediatrics, University of Thessaly School of Medicine and Larissa University Hospital, Larissa, Greece

CORRESPONDENCE: E. Kostadima, Chrisostomou Smirnis 2, Larissa, Greece. Fax: 30 2410670838. E-mail: ealexop@yahoo.com

Keywords: Bronchial asthma, bronchial hyperresponsiveness, clarithromycin, macrolides

Received: October 22, 2003
Accepted January 23, 2004

A randomised double-blind placebo-controlled study was designed to evaluate the effects of a semisynthetic macrolide antibiotic, clarithromycin, on bronchial hyperresponsiveness to methacholine in patients with a diagnosis of asthma.

Adult asthma patients undergoing treatment with budesonide 400 µg b.i.d. and salbutamol 200 µg p.r.n. less than twice weekly were studied. Arm A (16 males/six females, aged 48±16 yrs) received clarithromycin 250 mg b.i.d. for 8 weeks, arm B (eight males/12 females, aged 42±12 yrs) clarithromycin 250 mg t.i.d. and arm C (six males/15 females, aged 41±16 yrs) placebo dextrose tablets. Bronchial hyperresponsiveness was quantified by measurement of the provocative dose of methacholine causing a 20% fall in forced expiratory volume in one second (PD₂₀).

Median (interquartile range) PD₂₀ in the three groups before and after treatment with clarithromycin were: arm A: 0.3 (0.1–1) and 1.3 (0.6–2) mg; arm B: 0.4 (0.1–0.9) and 2 (2–2) mg; and arm C: 0.4 (0.1–0.9) and 0.3 (0.1–0.6) mg, respectively. Serum free cortisol levels were determined and remained unchanged from baseline in the clarithromycin-treated patients.

It is concluded that clarithromycin reduces the degree of bronchial hyperresponsiveness in patients with asthma.

This article has been cited by other articles:

				J. L. Simpson, H. Powell, M. J. Boyle, R. J. Scott, and P. G. Gibson Clarithromycin Targets Neutrophilic Airway Inflammation in Refractory Asthma Am. J. Respir. Crit. Care Med., January 15, 2008; 177(2): 148 - 155. [Abstract] [Full Text] [PDF]

				H. Kourlas Anti-inflammatory Properties of Macrolide Antibiotics Journal of Pharmacy Practice, October 1, 2006; 19(5): 326 - 329. [Abstract] [PDF]

				S C Bell, S L Senini, and J G McCormack Macrolides in cystic fibrosis Chronic Respiratory Disease, April 1, 2005; 2(2): 85 - 98. [Abstract] [PDF]

				E. Kostadima, S. Tsiodras, E. Alexopoulos, A. Kaditis, I. Mavrou, N. Georgatou, and A. Papamichalopoulos From the authors Eur. Respir. J., October 1, 2004; 24(4): 710 - 710. [Full Text] [PDF]

				G.P. Currie and D.K.C. Lee Methacholine and macrolides Eur. Respir. J., October 1, 2004; 24(4): 709 - 710. [Full Text] [PDF]